← Back to all trials
Recruiting
NCT07505199
Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy
Conditions: Ischemic Cardiomyopathy, Cell Therapy
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 30
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Location: Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang / 浙江
Summary
This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years and ≤75 years.
* Diagnosis of ischemic cardiomyopathy, with at least 3 months of optimized guideline-directed medical therapy (GDMT) at maximally tolerated doses; left ventricular ejection fraction (LVEF) \30%, lymphocyte count \>0.5 × 10⁹/L, and platelet count \>60 × 10⁹/L.
Exclusion Criteria:
* Life expectancy \
Source: ClinicalTrials.gov (NCT07505199). StuddyBuddy aggregates publicly available trial information.
